| Caretime Medical Clinic, Llc | |
|
1506 Highway 278 E Ste A Amory MS 38821-5906 | |
| (662) 597-2019 | |
| Not Available |
| Full Name | Caretime Medical Clinic, Llc |
|---|---|
| Speciality | Family Medicine |
| Location | 1506 Highway 278 E Ste A, Amory, Mississippi |
| Authorized Official Name and Position | Shannon Leianne Ballard (OWNER) |
| Authorized Official Contact | 6625972019 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Caretime Medical Clinic, Llc 1506 Highway 278 E Ste A Amory MS 38821-5906 Ph: (662) 597-2019 | Caretime Medical Clinic, Llc 1506 Highway 278 E Ste A Amory MS 38821-5906 Ph: (662) 597-2019 |
| NPI Number | 1700247855 |
|---|---|
| Provider Enumeration Date | 03/17/2016 |
| Last Update Date | 04/28/2016 |
| Medicare PECOS PAC ID | 4587953096 |
|---|---|
| Medicare Enrollment ID | O20160523000504 |
News Archive
Recently diagnosed cancer survivors are more likely to drink alcohol, use tobacco, and frequent tanning beds than people in later stages of recovery, according to a research team from the Virginia Tech Carilion Research Institute and Roswell Park Comprehensive Cancer Center.
The National Institutes of Health has awarded Dr. Daniel Geschwind, director of the UCLA Center for Autism Research and Treatment, a five-year, $10 million grant to continue his research on the genetic causes of autism spectrum disorders and to expand his investigations to include the genetics of autism in African Americans.
The researchers of the University of Helsinki, Finland, and école Polytechnique Fédérale de Lausanne, Switzerland, have shown that vitamin B3 form nicotinamide riboside can slow down the progression of mitochondrial disease, suggesting its potential as a novel therapy approach to adult-onset mitochondrial muscle diseases.
Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700247855 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Clinton L Washington |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1437163763 PECOS PAC ID: 3173530698 Enrollment ID: I20060308000518 |
News Archive
Recently diagnosed cancer survivors are more likely to drink alcohol, use tobacco, and frequent tanning beds than people in later stages of recovery, according to a research team from the Virginia Tech Carilion Research Institute and Roswell Park Comprehensive Cancer Center.
The National Institutes of Health has awarded Dr. Daniel Geschwind, director of the UCLA Center for Autism Research and Treatment, a five-year, $10 million grant to continue his research on the genetic causes of autism spectrum disorders and to expand his investigations to include the genetics of autism in African Americans.
The researchers of the University of Helsinki, Finland, and école Polytechnique Fédérale de Lausanne, Switzerland, have shown that vitamin B3 form nicotinamide riboside can slow down the progression of mitochondrial disease, suggesting its potential as a novel therapy approach to adult-onset mitochondrial muscle diseases.
Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).
› Verified 3 days ago
| Provider Name | Laura L Washington |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1093721151 PECOS PAC ID: 1254348774 Enrollment ID: I20060308000537 |
News Archive
Recently diagnosed cancer survivors are more likely to drink alcohol, use tobacco, and frequent tanning beds than people in later stages of recovery, according to a research team from the Virginia Tech Carilion Research Institute and Roswell Park Comprehensive Cancer Center.
The National Institutes of Health has awarded Dr. Daniel Geschwind, director of the UCLA Center for Autism Research and Treatment, a five-year, $10 million grant to continue his research on the genetic causes of autism spectrum disorders and to expand his investigations to include the genetics of autism in African Americans.
The researchers of the University of Helsinki, Finland, and école Polytechnique Fédérale de Lausanne, Switzerland, have shown that vitamin B3 form nicotinamide riboside can slow down the progression of mitochondrial disease, suggesting its potential as a novel therapy approach to adult-onset mitochondrial muscle diseases.
Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).
› Verified 3 days ago
| Provider Name | Shannon L Ballard |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275836991 PECOS PAC ID: 3779750948 Enrollment ID: I20120111000978 |
News Archive
Recently diagnosed cancer survivors are more likely to drink alcohol, use tobacco, and frequent tanning beds than people in later stages of recovery, according to a research team from the Virginia Tech Carilion Research Institute and Roswell Park Comprehensive Cancer Center.
The National Institutes of Health has awarded Dr. Daniel Geschwind, director of the UCLA Center for Autism Research and Treatment, a five-year, $10 million grant to continue his research on the genetic causes of autism spectrum disorders and to expand his investigations to include the genetics of autism in African Americans.
The researchers of the University of Helsinki, Finland, and école Polytechnique Fédérale de Lausanne, Switzerland, have shown that vitamin B3 form nicotinamide riboside can slow down the progression of mitochondrial disease, suggesting its potential as a novel therapy approach to adult-onset mitochondrial muscle diseases.
Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).
› Verified 3 days ago
| Provider Name | Elaina Ponder |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235783127 PECOS PAC ID: 2062839814 Enrollment ID: I20200825003861 |
News Archive
Recently diagnosed cancer survivors are more likely to drink alcohol, use tobacco, and frequent tanning beds than people in later stages of recovery, according to a research team from the Virginia Tech Carilion Research Institute and Roswell Park Comprehensive Cancer Center.
The National Institutes of Health has awarded Dr. Daniel Geschwind, director of the UCLA Center for Autism Research and Treatment, a five-year, $10 million grant to continue his research on the genetic causes of autism spectrum disorders and to expand his investigations to include the genetics of autism in African Americans.
The researchers of the University of Helsinki, Finland, and école Polytechnique Fédérale de Lausanne, Switzerland, have shown that vitamin B3 form nicotinamide riboside can slow down the progression of mitochondrial disease, suggesting its potential as a novel therapy approach to adult-onset mitochondrial muscle diseases.
Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).
› Verified 3 days ago
| Provider Name | Carl Andrew Ballard |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386243574 PECOS PAC ID: 3577971019 Enrollment ID: I20210421001587 |
News Archive
Recently diagnosed cancer survivors are more likely to drink alcohol, use tobacco, and frequent tanning beds than people in later stages of recovery, according to a research team from the Virginia Tech Carilion Research Institute and Roswell Park Comprehensive Cancer Center.
The National Institutes of Health has awarded Dr. Daniel Geschwind, director of the UCLA Center for Autism Research and Treatment, a five-year, $10 million grant to continue his research on the genetic causes of autism spectrum disorders and to expand his investigations to include the genetics of autism in African Americans.
The researchers of the University of Helsinki, Finland, and école Polytechnique Fédérale de Lausanne, Switzerland, have shown that vitamin B3 form nicotinamide riboside can slow down the progression of mitochondrial disease, suggesting its potential as a novel therapy approach to adult-onset mitochondrial muscle diseases.
Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).
› Verified 3 days ago
News Archive
Recently diagnosed cancer survivors are more likely to drink alcohol, use tobacco, and frequent tanning beds than people in later stages of recovery, according to a research team from the Virginia Tech Carilion Research Institute and Roswell Park Comprehensive Cancer Center.
The National Institutes of Health has awarded Dr. Daniel Geschwind, director of the UCLA Center for Autism Research and Treatment, a five-year, $10 million grant to continue his research on the genetic causes of autism spectrum disorders and to expand his investigations to include the genetics of autism in African Americans.
The researchers of the University of Helsinki, Finland, and école Polytechnique Fédérale de Lausanne, Switzerland, have shown that vitamin B3 form nicotinamide riboside can slow down the progression of mitochondrial disease, suggesting its potential as a novel therapy approach to adult-onset mitochondrial muscle diseases.
Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).
› Verified 3 days ago
Access Family Health Services, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 700 2nd Ave N, Amory, MS 38821 Phone: 662-256-5658 Fax: 662-651-4687 | |
Access School Health - Hatley Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 60286 Hatley Rd, Amory, MS 38821 Phone: 662-256-8808 Fax: 662-256-5626 | |
Mrh Medical Group, Amory Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 806 Earl Frye Blvd, Amory, MS 38821 Phone: 662-256-8479 | |
Amory Medical Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 404 Gilmore Dr, Amory, MS 38821 Phone: 662-256-3564 Fax: 662-256-3996 | |
Family Medicine Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 404 Gilmore Dr, Amory, MS 38821 Phone: 662-256-3564 Fax: 662-256-3996 | |
Priority Family & Urgent Care Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1208 Guy Pickle Rd, Amory, MS 38821 Phone: 662-256-3120 Fax: 662-256-7092 | |
Amory Specialty Clinic Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1107 Earl Frye Blvd Ste 6, Amory, MS 38821 Phone: 662-256-9327 |